Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based biotechnology companies Amgen and Genentech have entered into license agreements granting licenses to each other under multiple patents relating to the manufacture and use of antibodies and related technology.
Subscribe to our email newsletter
These agreements include a grant by Genentech to Amgen of a license for multiple antibodies relating in part to methods of producing immunoglobulins. Financial details of the license agreements were not disclosed.
Amgen also recently announced that it investing over $1 billion in a new manufacturing and process development facility in Cork, Ireland.
The new Irish facility is part of a general trend of expansion and inward investment for the company which is also expanding its existing R&D operations at sites in the US including Cambridge, Massachusetts, San Francisco and Seattle, adding a manufacturing facility in Puerto Rico, and is planning to build a new development center in Uxbridge, UK.